Drugs / FT-4101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04004325 | May 2019 → Jan 2020 | metabolic dysfunction-associated steatohepatitis, obesity disorder | Forma Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT-4101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04004325 ↗ |